EC investments in TB vaccine Research and Development through TBVI and its R&D partners have resulted in 6 TB vaccines currently being evaluated in clinical trials making up almost 50% of the [...]
The annual TBVI/TBVAC 2020 meeting was held in Les Diablerets, Switzerland from Feb 1-5 2016: 167 participants from 18 countries worldwide; participants represented 58 research [...]
This is a press release from our Research partners Institut Pasteur (Paris) and CNRS. It is the disappearance of a glycolipid from the bacterial cell envelope during evolution that may have [...]
Nacho Aguilo from our research partner University of Zaragoza has been selected as the inaugural recipient of the CTVD Early Career Scientist Award for his contributions to research in TB [...]
High quality vaccine research funded by the EUR 30 million FP7 High Impact Project on Advanced Immunization Technologies (ADITEC), in which TBVI is one of the partners, is confirmed by the [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: +31 320 277 550
